MedTrace Logo

Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in France

NCT06092879 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 201

Last updated 2026-02-06

No results posted yet for this study

Summary

The purpose of this study is to enhance the knowledge on asciminib treatment in a broader and real-life population by collecting additional data to characterize the treatment patterns of patients treated with asciminib, with a primary objective represented by maintenance on treatment at 12 months.

Conditions

  • Chronic Myeloid Leukemia

Interventions

OTHER

Asciminib

There is no treatment allocation. Patients administered Asciminib by prescription will be enrolled

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-06
Primary Completion
2026-12-15
Completion
2026-12-15

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06092879 on ClinicalTrials.gov